Maraviroc enhances Bortezomib sensitivity in multiple myeloma by inhibiting M2 macrophage polarization via PI3K/AKT/RhoA signaling pathway in macrophages

Table 1 Correlation of CCL3 and CCR5 expression with clinical and lab parameters in MM patients

Patient’s parameters	Total, median (range) (n = 37)	CD206 expression level		P value
Patient’s parameters	Total, median (range) (n = 37)	High, % (n = 21)	Low, % (n = 6)	P value
male (/female)	20/17	56.76	16.21	0.893
Age, ≥ 65 years	58 (43–76)	13.51	10.8`	0.818
ISS stage	III (II, III)	32.43	28.57	0.613
LDH, ≥ 230 IU/L	258 (138–639)	21.62	37.83	0.116
M-protein(g/l)	32.6(11.89–54.67)	48.65	18.91	0.004**
Relapase	18	40.54	8.11	0.002**
Cytogenetic abnormalities	18	36.8	15.8	0.033*

Abbreviations: MM, multiple myeloma; LDH, lactate dehydrogenase; ASPC, bone marrow aspiration plasma cells

ISSN: 1747-1028